IONQ Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? IONQ Inc trades at $39.9 (market cap $15.98B), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| IONQ | ROIV | |
|---|---|---|
Market Cap | $15.98B | $24.72B |
Volume | 22,848,240 | 6,279,442 |
Sector | Technology | Health |
52-Week High | $82.09 | $41.81 |
52-Week Low | $26.59 | $16.04 |
Typical Hold Time | 33 Days | 1 Days |
Enterprise Value | $13.92B | $20.99B |
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.89, down 3.51% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, with a high P/S ratio of 54.74. Recent news highlights Bank of America's Buy rating and $60 price target, citing IonQ's semiconductor-based quantum computing approach as a key growth driver.
The stock presents high-risk, high-reward potential with strong analyst optimism but faces significant execution risks amid widening losses. Upside depends on scaling quantum technology profitably, while downside risks include cash burn and competitive threats. The consensus price target of $62.75 suggests substantial upside if growth targets are met.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →